Deutsche Bank attended the investor briefing in the US. The focus of the briefing was on addressing some of the issues raised in the second quarter results. More insights were provided into the Verily joint venture with an overview of the Propeller Health acquisition.
Deutsche Bank increases earnings forecast by 1-2% for FY21-24. Management has guided to strong double-digit returns from investments which, if achieved, the broker suggests could provide 10% upside to FY22 forecasts. Buy rating and US$129 target.
Sector: Health Care Equipment & Services.
Current Price is $14.15. Target price not assessed.
